Bangladeshi physician Dr. Ashrafun Nahar has achieved success in in-vitro maturation (IVM) research aimed at treating infertility among women suffering from polycystic ovary syndrome (PCOS). Her team conducted the study at the Colorado Center for Reproductive Medicine in the United States, and the findings were presented at the American Society for Reproductive Medicine’s annual scientific congress and expo. The research identified the benefits of antioxidant supplementation in oocytes, showing particular promise for PCOS patients.

According to the study, IVM is an advanced assisted reproductive technology that matures immature eggs outside the body, reducing the need for hormone injections compared to IVF. The research involved 15 patients with an average age of 30.5 years, average BMI of 28.5 kg/m², and average anti-Müllerian hormone level of 8.5 ng/mL. The process used minimal hormonal stimulation and avoided human chorionic gonadotropin triggers. Some oocytes were matured with mitoquinone to assess antioxidant effects.

The study reported five live births from the current IVM research and a total of 14 IVM births at the Colorado center, highlighting the potential of this low-risk fertility treatment for PCOS patients.